97 related articles for article (PubMed ID: 4016785)
1. Prospectively randomized toxicity study of high-dose versus low-dose treatment strategies for lymphoblastoid interferon.
Silver HK; Connors JM; Salinas FA
Cancer Treat Rep; 1985; 69(7-8):743-50. PubMed ID: 4016785
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of weekly high-dose human lymphoblastoid interferon.
Connors JM; Silver HK
Cancer Treat Rep; 1984 Sep; 68(9):1093-6. PubMed ID: 6478449
[TBL] [Abstract][Full Text] [Related]
3. Phase I evaluation of therapy with four schedules of 5-fluorouracil by continuous infusion combined with recombinant interferon alpha.
Greenblatt MS; Mangalik A; Ferguson J; Elias L
Clin Cancer Res; 1995 Jun; 1(6):615-20. PubMed ID: 9816023
[TBL] [Abstract][Full Text] [Related]
4. Randomized phase II studies in advanced colorectal carcinoma: a North Central Cancer Treatment Group study.
Windschitl H; Scott M; Schutt A; McCormack G; Everson L; Cullinan S; Gerstner J; Krook J; Laurie J; Shreck R
Cancer Treat Rep; 1983 Nov; 67(11):1001-8. PubMed ID: 6640551
[TBL] [Abstract][Full Text] [Related]
5. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
[TBL] [Abstract][Full Text] [Related]
6. [Phase I study of a recombinant gamma interferon (S-6810)].
Ogawa M; Takaku F; Maekawa T; Ota K; Ichimaru M; Izuo M; Takakura K; Ikeda S; Koiso K; Machida T
Gan To Kagaku Ryoho; 1987 Feb; 14(2):446-52. PubMed ID: 3101608
[TBL] [Abstract][Full Text] [Related]
7. Phase I evaluation of a synthetic mutant of beta-interferon.
Hawkins M; Horning S; Konrad M; Anderson S; Sielaff K; Rosno S; Schiesel J; Davis T; DeMets D; Merigan T
Cancer Res; 1985 Nov; 45(11 Pt 2):5914-20. PubMed ID: 4053062
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of recombinant beta-interferon given by four-hour infusion.
Grunberg SM; Kempf RA; Venturi CL; Mitchell MS
Cancer Res; 1987 Feb; 47(4):1174-8. PubMed ID: 3802098
[TBL] [Abstract][Full Text] [Related]
9. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
10. [Phase I study of human lymphoblastoid alpha-interferon on malignant tumor].
Furue H
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 1):977-83. PubMed ID: 3963861
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of lymphoblastoid interferon in metastatic colon carcinoma.
Chaplinski T; Laszlo J; Moore J; Silverman P
Cancer Treat Rep; 1983 Nov; 67(11):1009-12. PubMed ID: 6640552
[TBL] [Abstract][Full Text] [Related]
12. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
13. Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic study.
Hochster H; Liebes L; Speyer J; Sorich J; Taubes B; Oratz R; Wernz J; Chachoua A; Blum RH; Zeleniuch-Jacquotte A
Clin Cancer Res; 1997 Aug; 3(8):1245-52. PubMed ID: 9815806
[TBL] [Abstract][Full Text] [Related]
14. Human alpha-lymphoblastoid interferon. A phase I study including pharmacokinetics and effects on hematologic stem cells (CFU-GMs).
Sarna G; Figlin R; Bryson Y; Garratty E; Myers L; Le Fevre C; Mauritzon N; Cline M
Am J Clin Oncol; 1985 Oct; 8(5):406-12. PubMed ID: 4061375
[TBL] [Abstract][Full Text] [Related]
15. A phase II trial of high-dose human lymphoblastoid alpha interferon in patients with advanced renal carcinoma.
Vugrin D; Hood L; Laszlo J
J Biol Response Mod; 1986 Aug; 5(4):309-12. PubMed ID: 3734846
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of alpha-lymphoblastoid interferon given weekly as treatment of advanced breast cancer.
Sarna GP; Figlin RA
Cancer Treat Rep; 1985 May; 69(5):547-9. PubMed ID: 4005877
[TBL] [Abstract][Full Text] [Related]
17. [Phase II studies of interferon alpha-2 Sch 30500 in advanced gastrointestinal carcinoma].
Furue H
Gan To Kagaku Ryoho; 1985 Aug; 12(8):1625-9. PubMed ID: 3896154
[TBL] [Abstract][Full Text] [Related]
18. A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors.
Hurwitz HI; Cohen RB; McGovren JP; Hirawat S; Petros WP; Natsumeda Y; Yoshinari T
Cancer Chemother Pharmacol; 2007 Jan; 59(1):139-47. PubMed ID: 16819636
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of natural human interferon beta in metastatic malignancy.
Bukowski RM; Sergi JS; Sharfman WJ; Budd GT; Murthy S; Barna B; Medendorp SV; Yen-Lieberman B; Gibson V; Bauer L
Cancer Res; 1991 Feb; 51(3):836-40. PubMed ID: 1988123
[TBL] [Abstract][Full Text] [Related]
20. Human leukocyte (alpha) interferon in metastatic malignant melanoma: the American Cancer Society phase II trial.
Krown SE; Burk MW; Kirkwood JM; Kerr D; Morton DL; Oettgen HF
Cancer Treat Rep; 1984 May; 68(5):723-6. PubMed ID: 6722830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
